- Published on
Clinical Toxicology — Selective Serotonin Reuptake Inhibitors
1. Overview
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed antidepressants used to treat depressive disorders, anxiety disorders, obsessive-compulsive disorder, panic disorder, and several other psychiatric conditions.
They increase serotonergic neurotransmission by inhibiting the serotonin transporter.
SSRIs generally have a wider safety margin in isolated overdose than tricyclic antidepressants. Nevertheless, significant poisoning can produce seizures, serotonin toxicity, cardiac conduction abnormalities, hyperthermia, and, rarely, death.
Three major clinical hazards must be recognized:
- Dose-related toxicity after overdose, especially involving citalopram and escitalopram.
- Serotonin toxicity, particularly after interactions with other serotonergic medications.
- Treatment-related adverse effects, including hyponatremia, abnormal bleeding, and withdrawal symptoms after abrupt discontinuation.
There is no universal antidote for SSRI poisoning.
Management is primarily supportive, with specific attention to the ECG, neuromuscular examination, temperature, and coingested medications.
2. Drugs included in the SSRI class
The principal SSRIs are:
Fluoxetine (Prozac): Used for depression, obsessive-compulsive disorder, panic disorder, bulimia nervosa, and selected other conditions.
Sertraline (Zoloft): Used for depression, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder.
Paroxetine (Paxil): Used for depression and several anxiety-related disorders.
Fluvoxamine (Luvox): Particularly associated with treatment of obsessive-compulsive disorder.
Citalopram (Celexa): Used for depression.
Escitalopram (Lexapro): The S-enantiomer of citalopram, used for depression and anxiety disorders.
Vilazodone (Viibryd): Inhibits serotonin reuptake and also acts as a partial serotonin 5-HT1A receptor agonist. It is sometimes categorized separately as a serotonin partial agonist–reuptake inhibitor.
Important classification distinction
Venlafaxine, desvenlafaxine, and duloxetine are serotonin–norepinephrine reuptake inhibitors (SNRIs), not SSRIs.
Venlafaxine overdose is associated with a substantially greater risk of serious seizures and cardiovascular complications than most SSRI overdoses.
Similarly, bupropion is not an SSRI and carries important risks of delayed seizures and cardiotoxicity.
These medications require separate poisoning protocols.
3. Mechanism of action and toxicokinetics
Serotonin transporter inhibition
SSRIs inhibit presynaptic serotonin reuptake, increasing serotonin availability in the synaptic cleft.
The therapeutic antidepressant effect develops through subsequent neurobiological adaptations rather than simply reflecting the immediate increase in serotonin concentration.
Pharmacokinetic differences
Most SSRIs undergo hepatic metabolism.
Their elimination half-lives and drug-interaction profiles vary.
Fluoxetine has a particularly long elimination half-life, approximately one to four days after initial use and longer following sustained treatment.
Its active metabolite, norfluoxetine, may have an elimination half-life of approximately four to sixteen days.
Sertraline has a half-life of approximately 26 hours.
Paroxetine has a half-life of approximately 21 hours.
Citalopram and escitalopram generally have half-lives around 27–35 hours.
Fluvoxamine has a shorter and dose-dependent half-life, commonly around 15–22 hours.
Important correction
The historical statement that fluoxetine is the only SSRI with an active metabolite is inaccurate.
Other SSRIs have metabolites with varying degrees of pharmacologic activity, although norfluoxetine is especially important because of its prolonged persistence.
Clinical implication
Fluoxetine can cause clinically important interactions for several weeks after treatment is discontinued.
However, the persistence of a metabolite does not mean that every patient experiences overdose symptoms for several weeks.
4. Toxic dose
There is no single toxic-dose threshold for the entire SSRI class.
Toxicity depends on the specific drug, the amount ingested, patient characteristics, formulation, and coingestants.
Isolated overdose
Most patients with isolated SSRI overdose develop no symptoms or relatively mild effects.
Nausea, vomiting, tremor, dizziness, somnolence, and sinus tachycardia are typical findings.
Severe poisoning
Substantial ingestion can produce seizures, serotonin toxicity, altered consciousness, and cardiac complications.
The historical assertion that ingestion of gram quantities of any SSRI generally causes minimal toxicity should not be retained.
It is particularly inappropriate for citalopram and escitalopram.
Pediatric accidental ingestion
The Royal Children’s Hospital Melbourne guideline identifies the following approximate thresholds for medical assessment after accidental pediatric ingestion:
- Citalopram: more than 2 mg/kg.
- Escitalopram: more than 1 mg/kg.
- Fluoxetine: more than 5 mg/kg or 60 mg, whichever is less.
- Fluvoxamine: more than 10 mg/kg or 100 mg, whichever is less.
- Paroxetine: more than 5 mg/kg or 60 mg, whichever is less.
- Sertraline: more than 10 mg/kg.
These thresholds apply to accidental pediatric exposure under that guideline. They must not be extrapolated directly to adults or intentional adolescent overdoses.
5. Clinical manifestations
Gastrointestinal effects
Nausea, vomiting, abdominal discomfort, and diarrhea are common.
Neurologic effects
Possible findings include:
- Drowsiness.
- Dizziness.
- Tremor.
- Restlessness.
- Ataxia.
- Agitation.
- Hyperreflexia.
- Myoclonus.
- Seizures.
Profound coma is unusual after isolated overdose of most SSRIs and should prompt evaluation for coingestants or other diagnoses.
Cardiovascular effects
Sinus tachycardia is common.
Bradycardia, QT prolongation, and ventricular dysrhythmias are less common.
Citalopram and escitalopram are particularly important because they can cause dose-dependent QT prolongation and torsades de pointes.
Temperature abnormalities
Severe hyperthermia is not typical of uncomplicated SSRI overdose.
Its presence should raise concern for serotonin toxicity or another serious complication.
Metabolic complications
Severe agitation, seizures, hyperthermia, and sustained muscle activity may produce lactic acidosis, rhabdomyolysis, and acute kidney injury.
6. Serotonin toxicity
Serotonin toxicity, also called serotonin syndrome, is a potentially life-threatening condition caused by excessive serotonergic activity in the nervous system.
It most commonly follows overdose, the addition of another serotonergic medication, or a significant change in drug exposure.
Characteristic clinical features
The syndrome involves three broad domains.
Neuromuscular excitation: Clonus, tremor, hyperreflexia, myoclonus, and muscle rigidity.
Autonomic activation: Diaphoresis, tachycardia, hypertension, diarrhea, and hyperthermia.
Mental-status changes: Agitation, anxiety, confusion, or delirium.
Importance of clonus
Clonus is among the most useful findings when serotonin toxicity is suspected.
It may be spontaneous, inducible at the ankle, or manifest as abnormal ocular movements.
Hyperreflexia and clonus are often particularly prominent in the lower extremities.
Mild toxicity
Patients may have tremor, increased reflexes, sweating, and mild agitation.
Moderate toxicity
Patients may develop sustained clonus, more pronounced agitation, tachycardia, and elevated temperature.
Severe toxicity
Severe cases involve marked muscle rigidity, dangerous hyperthermia, impaired ventilation, metabolic acidosis, rhabdomyolysis, disseminated intravascular coagulation, and multiorgan failure.
Severe hyperthermia with rigidity is a medical emergency.
7. Hunter Serotonin Toxicity Criteria
The Hunter criteria are widely used clinical decision rules.
In a patient with relevant serotonergic drug exposure, serotonin toxicity is supported by any one of the following:
- Spontaneous clonus.
- Inducible clonus accompanied by agitation or sweating.
- Ocular clonus accompanied by agitation or sweating.
- Tremor accompanied by hyperreflexia.
- Hypertonia with temperature above 38°C and ocular or inducible clonus.
Performance
In their original overdose-based validation, the Hunter criteria demonstrated approximately 84% sensitivity and 97% specificity compared with clinical toxicologist assessment.
Important limitation
These criteria were principally developed and validated in patients with serotonergic overdose.
They should not be treated as a perfect diagnostic test in every therapeutic or medically complex setting.
Diagnosis remains clinical, and alternative causes of fever, rigidity, agitation, or altered consciousness must be assessed.
8. High-risk drug interactions
Drug interactions are among the most important causes of severe serotonin toxicity.
Monoamine oxidase inhibitors
Combining an SSRI with an MAOI can cause life-threatening serotonin toxicity.
Examples of MAOIs include phenelzine and tranylcypromine.
Linezolid
Linezolid has monoamine oxidase inhibitory activity and can precipitate serotonin toxicity in susceptible patients receiving serotonergic medications.
Methylene blue
Intravenous methylene blue can inhibit monoamine oxidase A and has caused severe serotonin toxicity when administered to patients taking SSRIs.
Tramadol
Tramadol inhibits serotonin and norepinephrine reuptake.
Combining it with an SSRI can increase serotonin toxicity risk, while also introducing opioid and seizure-related hazards.
Dextromethorphan
Dextromethorphan-containing cough products can contribute to serotonin toxicity, especially when combined with SSRIs or drugs that inhibit their metabolism.
Recreational drugs
MDMA and certain other recreational substances can substantially increase serotonergic activity.
Other interactions
Lithium, certain antidepressants, St. John’s wort, and selected opioids may contribute to serotonin toxicity in particular combinations.
Important qualification
Not every medication historically described as serotonergic creates the same risk.
For example, the absolute risk of serotonin toxicity with appropriately prescribed triptans plus SSRIs appears low, despite longstanding interaction warnings.
Clinical risk assessment should consider the actual pharmacology and circumstances rather than treating every possible combination as equally dangerous.
9. Drug-interaction washout periods
Fluoxetine to an MAOI
The FDA recommends waiting at least five weeks after stopping fluoxetine before starting an MAOI intended for psychiatric treatment.
An even longer interval may be appropriate in selected patients after prolonged high-dose treatment.
MAOI to fluoxetine
At least 14 days should elapse after discontinuing a conventional irreversible psychiatric MAOI before starting fluoxetine.
Other SSRIs
For most other SSRIs, a shorter washout than fluoxetine is usually appropriate when switching to an MAOI, but the exact interval depends on the medications and their prescribing information.
Correction to the historical text
It is incorrect to recommend withholding every potentially interacting medication for six weeks after discontinuing any SSRI.
The extended washout is particularly important with fluoxetine.
Urgent use of medications such as linezolid requires individualized risk-benefit assessment and specialist management rather than an automatic rule applied without regard to the severity of infection.
10. Citalopram and escitalopram cardiotoxicity
These medications deserve separate consideration in overdose.
Mechanism
Both can delay cardiac repolarization, producing QT prolongation.
Substantial overdose may also cause additional conduction abnormalities.
Clinical findings
Patients may develop:
- QTc prolongation.
- Bradycardia.
- Ventricular ectopy.
- Torsades de pointes.
- Other serious ventricular dysrhythmias.
Delayed abnormalities
QT prolongation may occur after plasma concentrations have already peaked.
Consequently, an initially reassuring ECG does not always exclude subsequent cardiotoxicity after a large ingestion.
Evaluation
Obtain a 12-lead ECG.
Continuous cardiac monitoring and serial ECGs are appropriate after significant citalopram or escitalopram overdose.
The required monitoring period depends on dose, ECG findings, coingestants, and poison-center guidance.
Treatment
Correct potassium and magnesium abnormalities.
Avoid additional QT-prolonging medications.
Treat torsades de pointes according to current resuscitation protocols, including intravenous magnesium sulfate and appropriate electrical treatment when indicated.
Routine prophylactic antiarrhythmic administration is not recommended.
11. Diagnosis and investigations
Exposure history
Determine the exact SSRI, dose, time, formulation, and other medications taken.
Ask specifically about MAOIs, tramadol, linezolid, methylene blue, dextromethorphan, and recreational substances.
Initial assessment
Evaluate airway, respiratory effort, mental status, temperature, circulation, and neuromuscular findings.
Assess pupils, reflexes, muscle tone, and the presence of spontaneous or inducible clonus.
ECG
An ECG is appropriate after significant or intentional SSRI overdose.
Serial ECG monitoring is particularly important with citalopram and escitalopram.
Laboratory testing
Investigations may include:
- Blood glucose.
- Electrolytes, including potassium.
- Creatinine and kidney function.
- Acetaminophen concentration after intentional or uncertain ingestion.
- Blood gas and lactate in severe toxicity.
- Creatine kinase when muscle rigidity, hyperthermia, or prolonged seizures occur.
- Liver tests and coagulation studies when severe systemic injury is present.
Drug concentrations
Routine serum SSRI concentrations are not clinically useful for emergency decision-making.
Toxicology screening
Routine urine drug screens may not detect SSRIs and do not reliably identify serotonin toxicity.
12. Treatment of uncomplicated overdose
Initial management
Treatment is primarily supportive.
Maintain adequate ventilation and circulation.
Observe for evolving symptoms and identify clinically important coingestants.
Gastrointestinal decontamination
Do not induce vomiting.
Routine gastric lavage is not recommended.
Activated charcoal
Activated charcoal is rarely necessary for uncomplicated isolated SSRI ingestion.
A single dose may be considered after a substantial recent ingestion when the airway is protected.
There is specific pharmacokinetic evidence supporting consideration after large citalopram or escitalopram ingestion because charcoal can reduce absorption and the probability of abnormal QT intervals.
This should be discussed with a poison center or medical toxicologist.
Enhanced elimination
Multiple-dose activated charcoal, hemodialysis, and hemoperfusion are not routinely useful for SSRI removal.
Their large volumes of distribution and other pharmacokinetic properties generally limit extracorporeal clearance.
Seizures
Benzodiazepines are first-line treatment.
Persistent seizures require escalation according to contemporary status epilepticus protocols.
13. Treatment of serotonin toxicity
Stop the causative agents
Immediately discontinue the suspected serotonergic medications.
Identify interactions that may prolong or intensify toxicity.
Mild toxicity
Mild cases often improve following withdrawal of the offending medication and supportive care.
Benzodiazepines may reduce agitation and neuromuscular excitation when clinically indicated.
Moderate toxicity
Provide appropriate intravenous fluids and close monitoring.
Use benzodiazepines for agitation, tremor, clonus, or severe muscular activity.
Assess temperature and progression frequently.
Severe toxicity
Patients with pronounced rigidity, hyperthermia, altered consciousness, or organ dysfunction require critical-care management.
Important interventions include:
Rapid active cooling: Use appropriate external cooling techniques.
Reduction of muscle activity: Benzodiazepines are important initial treatment.
Airway and ventilation: Severe rigidity or respiratory compromise may require intubation and mechanical ventilation.
Neuromuscular paralysis: Severe hyperthermia associated with uncontrolled muscle activity may require a nondepolarizing neuromuscular blocker under appropriate critical-care conditions.
Management of complications: Monitor and treat rhabdomyolysis, acute kidney injury, metabolic acidosis, and coagulopathy.
Antipyretics
Acetaminophen and other conventional antipyretics are generally ineffective for serotonin toxicity–related hyperthermia because the heat is predominantly generated by excessive muscle activity rather than a change in hypothalamic temperature regulation.
Rapid cooling and control of muscular activity are the priorities.
14. Cyproheptadine
Cyproheptadine is an antihistamine with serotonin receptor antagonist properties, including 5-HT2A antagonism.
It has historically been recommended for serotonin toxicity.
Potential role
Cyproheptadine may be considered in selected patients with persistent mild or moderate serotonin toxicity despite supportive treatment.
It is administered orally or through a suitable enteral tube because an intravenous formulation is not available.
Evidence limitations
A 2025 systematic review found that the evidence for its effectiveness in deliberate self-poisoning is largely limited to case reports and small series.
No convincing clinical outcome benefit has been established.
Severe toxicity
Cyproheptadine must not delay rapid cooling, sedation, airway management, or control of muscle rigidity.
It should not be described as a proven lifesaving antidote.
15. Differential diagnosis
Neuroleptic malignant syndrome
Neuroleptic malignant syndrome may cause rigidity, fever, autonomic instability, and altered mental status.
It typically develops over a longer period and is associated with dopamine receptor blockade.
Clonus and marked hyperreflexia more strongly suggest serotonin toxicity.
Anticholinergic poisoning
Anticholinergic poisoning commonly produces dry skin, dry mucous membranes, urinary retention, and reduced bowel sounds.
Serotonin toxicity more typically produces diaphoresis, hyperreflexia, and clonus.
Sympathomimetic poisoning
Amphetamine and cocaine toxicity may produce agitation, tachycardia, hypertension, sweating, and hyperthermia.
Marked clonus is a useful distinguishing feature.
Other disorders
Sepsis, meningitis, encephalitis, thyroid storm, malignant hyperthermia, sedative withdrawal, and other metabolic or neurologic disorders may resemble serotonin toxicity.
16. Other treatment-related adverse effects
Hyponatremia
SSRIs can cause syndrome of inappropriate antidiuresis, often described clinically as SIADH.
Older adults, patients taking thiazide diuretics, and those with other risk factors are particularly susceptible.
Symptoms may include nausea, weakness, confusion, seizures, and altered consciousness.
Hyponatremia can occur during therapeutic treatment rather than overdose.
Bleeding
SSRIs impair serotonin uptake into platelets and may increase bleeding risk.
The risk is greater when combined with aspirin, NSAIDs, anticoagulants, or other drugs affecting hemostasis.
Discontinuation syndrome
Abrupt SSRI discontinuation may cause dizziness, anxiety, insomnia, nausea, sensory disturbances, and flu-like symptoms.
Paroxetine is particularly associated with discontinuation symptoms because of its relatively short half-life.
Fluoxetine generally causes fewer immediate discontinuation symptoms because it and norfluoxetine are eliminated slowly.
Sexual adverse effects
Sexual dysfunction is common during SSRI treatment and may include reduced libido, delayed ejaculation, and difficulty achieving orgasm.
These effects should not be described as rare.
Suicidality warning
Antidepressants carry an FDA boxed warning concerning increased suicidal thoughts and behaviors in pediatric and young adult patients during short-term studies.
Treatment requires appropriate monitoring, particularly during initiation and dose changes.
This warning does not mean antidepressants are ineffective or should be withheld indiscriminately.
17. Pregnancy and breastfeeding
Pregnancy
The old FDA pregnancy categories are obsolete.
SSRIs are commonly prescribed during pregnancy when treatment is clinically indicated.
The risks of medication exposure must be balanced against the consequences of untreated or undertreated maternal mental illness.
ACOG recommends SSRIs as first-line pharmacotherapy for many perinatal depression and anxiety disorders.
Sertraline and escitalopram are commonly considered reasonable first-line options when there is no relevant prior treatment history.
Neonatal adaptation
Late-pregnancy SSRI exposure may be associated with transient neonatal symptoms such as jitteriness, respiratory difficulties, feeding problems, or altered muscle tone.
These symptoms are often referred to as poor neonatal adaptation syndrome.
Persistent pulmonary hypertension
Some studies suggest a small increase in the risk of persistent pulmonary hypertension of the newborn following late-pregnancy SSRI exposure.
The absolute risk remains low, and findings across studies are not entirely consistent.
Breastfeeding
Many SSRIs are compatible with breastfeeding.
Sertraline is commonly preferred because breastmilk concentrations are low and infant serum concentrations are usually undetectable.
Infants should receive ordinary clinical monitoring for feeding and growth, with additional assessment when indicated.
Important clinical principle
Patients should not abruptly stop a prescribed SSRI merely because pregnancy or breastfeeding is identified.
Treatment decisions should be individualized with the prescribing clinician.
18. Observation and disposition
Mild isolated overdose
Most mild isolated SSRI overdoses have a favorable course.
Symptoms typically begin within several hours.
Many patients recover within approximately 12–24 hours.
Pediatric observation
The Royal Children’s Hospital Melbourne recommends approximately 12 hours of observation for children and adolescents requiring assessment after SSRI poisoning.
This is more conservative than the historical six-hour recommendation.
Citalopram and escitalopram
Large ingestions may require prolonged ECG monitoring because of delayed or persistent QT abnormalities.
Hospital admission
Admission is appropriate for significant symptoms, seizures, serotonin toxicity, QT prolongation, abnormal vital signs, or important coingestants.
Intensive care
ICU treatment is required for severe hyperthermia, uncontrolled rigidity, recurrent seizures, respiratory failure, significant dysrhythmias, or multiorgan dysfunction.
Discharge
Discharge requires:
- Return to baseline mental status.
- Stable vital signs.
- Resolution of clinically important neuromuscular findings.
- Reassuring ECG findings.
- Adequate assessment of coingestants.
- Completion of an appropriate observation period.
Intentional overdose requires a suitable mental health and safety assessment before discharge.
No universal six-hour discharge rule is appropriate for every SSRI or exposure pattern.
19. Expected course and prognosis
Most patients with isolated SSRI poisoning recover completely with supportive care.
Seizures and serious dysrhythmias are uncommon compared with overdoses involving many tricyclic antidepressants or certain SNRIs.
Severe serotonin toxicity may cause hyperthermia, rhabdomyolysis, kidney injury, disseminated intravascular coagulation, and death.
The prognosis depends substantially on the speed with which severe muscular activity and hyperthermia are controlled.
Fluoxetine’s long elimination half-life may prolong drug interactions, but severe symptoms do not necessarily persist throughout the entire elimination period.
20. Clinical pitfalls
Assuming all SSRIs have identical overdose risks. Citalopram and escitalopram require particular cardiac attention.
Believing gram quantities of SSRIs are universally safe. Severe toxicity can occur after substantial ingestion.
Missing serotonin toxicity after medication changes. Drug interactions can cause life-threatening toxicity without an intentional overdose.
Diagnosing serotonin toxicity from fever alone. Clonus and hyperreflexia are particularly important examination findings.
Assuming the Hunter criteria are perfectly validated in all settings. Their strongest validation is in overdose populations.
Overlooking methylene blue or linezolid. Both can interact dangerously with serotonergic medications.
Applying a six-week washout to every SSRI. Extended washout is most important after fluoxetine.
Failing to recognize delayed QT abnormalities. Significant citalopram or escitalopram overdose may require serial ECGs.
Using routine ipecac or gastric lavage. These historical treatments should be removed.
Giving activated charcoal automatically. It is rarely indicated in uncomplicated SSRI overdose.
Assuming cyproheptadine is a proven lifesaving antidote. Clinical benefit remains uncertain.
Treating serotonin-related hyperthermia with antipyretics alone. Active cooling and reduction of muscle activity are essential.
Ignoring hyponatremia during therapeutic treatment. It can cause severe neurologic symptoms, particularly in older adults.
Assuming every SSRI is equally suitable during pregnancy or breastfeeding. Individual clinical circumstances and medication-specific evidence matter.
Stopping long-term SSRI treatment abruptly. Discontinuation symptoms and recurrence of the underlying illness may result.
Key clinical conclusions
SSRIs are generally safer than tricyclic antidepressants in isolated overdose, but they are not uniformly benign.
Citalopram and escitalopram have important dose-related cardiac risks, including QT prolongation and potentially serious ventricular dysrhythmias.
Serotonin toxicity is characterized by neuromuscular excitation, autonomic activation, and mental-status changes. Clonus and hyperreflexia are particularly valuable diagnostic findings.
Most uncomplicated SSRI overdoses require supportive care rather than gastrointestinal decontamination.
Severe serotonin toxicity demands immediate withdrawal of serotonergic drugs, benzodiazepines, active cooling, and, when necessary, intubation and neuromuscular paralysis.
Cyproheptadine may be considered as an adjunct in selected cases, but it has no proven benefit over effective supportive resuscitation in life-threatening toxicity.
Clinical decisions should be based on the specific medication, exposure severity, interacting drugs, examination, ECG, and clinical progression.